文献速递类风湿关节炎

英国风湿病学会类风湿关节炎生物制剂注册中宫颈筛查参与率及宫颈异型增生率

Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究将BSRBR-RA与英国宫颈筛查计划链接,比较12 785名RA女性与普通人群的宫颈筛查参与率及宫颈细胞学异常率。结果显示RA女性5年筛查覆盖率(83%)高于普通人群(79%),但高残疾女性覆盖率(78%)低于低残疾女性(85%);RA女性高级别宫颈异型增生(HGCD)风险差异低于国家统计,低级别(LGCD)风险差异更高;bDMARD暴露与未暴露女性间HGCD或LGCD率无统计学显著差异。

要点

  • RA女性宫颈筛查覆盖率高于普通人群,但高残疾者覆盖率较低。
  • RA女性HGCD风险差异低于国家统计,LGCD风险差异更高。
  • bDMARD暴露与否不影响宫颈异型增生率。

核心结论

  • RA女性宫颈筛查率高于普通人群,残疾 negatively 影响参与率,但治疗类型不影响。
  • RA女性HGCD风险未高于国家统计,且不受bDMARD暴露影响。

研究设计与样本

  • 英国风湿病学会类风湿关节炎生物制剂注册(BSRBR-RA)是一项全国性前瞻性研究,与NHS宫颈筛查计划链接,提供12 785名女性数据与国家筛查数据比较。
  • 采用风险差异计算比较BSRBR-RA与国家统计的HGCD/LGCD率与阴性涂片率。
  • 在BSRBR-RA内部比较低与高身体残疾评分者的覆盖率,以及bDMARD未暴露与暴露者的覆盖率和细胞学结果。

主要发现

  • BSRBR-RA平均5年筛查覆盖率为83%,显著高于普通人群的79%。
  • 高残疾女性覆盖率78%,低于较低残疾女性的85%。
  • BSRBR-RA相比国家统计,HGCD风险差异较低,而LGCD风险差异较高。
  • bDMARD暴露与未暴露女性间HGCD或LGCD率无统计学显著差异。

关键数值与推荐

  • 平均5年筛查覆盖率:BSRBR-RA 83% vs 普通人群79%。
  • 高残疾女性覆盖率78% vs 较低残疾女性85%。
  • HGCD风险差异低于国家统计,LGCD风险差异高于国家统计。
  • bDMARD暴露与未暴露女性HGCD/LGCD率无统计学显著差异。

临床怎么用

  • RA女性宫颈筛查参与率较高,但仍需关注高残疾女性的筛查障碍。
  • bDMARD治疗状态不应作为宫颈筛查或异型增生风险分层的依据。
  • RA女性HGCD风险不高于普通人群,可按常规指南进行宫颈筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare cervical screening attendance and cytology (high- and low-grade cervical dysplasia [HGCD and LGCD]) between women with RA and the English general population and between biologic DMARD (bDMARD)-naïve and exposed women. METHODS: The British Society for Rheumatology Biologics Register for RA (BSRBR-RA), a national prospective study of RA treatment outcomes, was linked to the National Health Service Cervical Screening Programme, providing data for 12 785 women to compare with national screening data. Rates of HGCD/LGCD were compared with rates of negative smears using risk difference calculations between BSRBR-RA and national statistics. Within the BSRBR-RA, coverage was compared between those with low and high physical disability scores, while coverage and cytology results were compared between bDMARD-naïve and -exposed RA patients. RESULTS: The mean 5 year screening coverage was significantly higher in BSRBR-RA (83%) compared with the general population (79%), but lower in women with high disability (78%) compared with lesser disability (85%). Risk differences for HGCD were lower in the BSRBR-RA compared with national statistics, whereas risk differences for LGCD were higher. There was no statistically significant difference in the rates of HGCD or LGCD between bDMARD-exposed and -naïve women. CONCLUSION: This first-ever British analysis of cervical screening rates in RA has shown that women with RA have higher screening rates than the general population. Disability negatively impacts attendance, but treatment type does not. Women with RA did not have an increased risk of HGCD compared with national statistics, which was also not influenced by bDMARD exposure.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chadwick L, Kearsley-Fleet L, Brown N, et al. Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2020. PMID: 31722431. doi:10.1093/rheumatology/kez277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。